ADAM17（解整合素金屬蛋白酶17）又稱TACE（腫瘤壞死因子α轉(zhuǎn)化酶），是一種跨膜蛋白酶，主要參與細(xì)胞表面蛋白的裂解和信號(hào)傳導(dǎo)調(diào)控。ADAM17通過剪切多種膜錨定分子（如TNF-α、EGFR配體及Notch受體等），在炎癥反應(yīng)、表皮生長(zhǎng)及免疫調(diào)節(jié)中發(fā)揮關(guān)鍵作用。其活性異常與類風(fēng)濕性關(guān)節(jié)炎、銀屑病等自身免疫疾病密切相關(guān)，同時(shí)也在結(jié)直腸癌、乳腺癌等惡性腫瘤的侵襲轉(zhuǎn)移過程中起促進(jìn)作用。近年來研究發(fā)現(xiàn)，ADAM17可通過激活EGFR信號(hào)通路加速腫瘤細(xì)胞增殖，并與阿爾茨海默病中淀粉樣蛋白前體的加工存在潛在關(guān)聯(lián)。
針對(duì)ADAM17的藥物研發(fā)聚焦于抑制其蛋白酶活性，已有多個(gè)小分子抑制劑（如INCB7839、BMS-561392）進(jìn)入臨床試驗(yàn)階段，嘗試用于三陰性乳腺癌和急性髓系白血病的治療。單克隆抗體類藥物如MEDI3622則通過阻斷ADAM17與底物結(jié)合發(fā)揮作用，但部分藥物因影響生理功能而存在安全性問題，其特異性抑制策略和疾病適應(yīng)癥仍在持續(xù)探索中。

熱銷產(chǎn)品

ADAM17 Recombinant Monoclonal Antibody (CSB-RA797631A0HU)

驗(yàn)證數(shù)據(jù)

Immunofluorescence staining of Hela Cells with CSB-RA797631A0HU at 1:50, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeated by 0.2% TritonX-100, and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4℃. Nuclear DNA was labeled in blue with DAPI. The secondary antibody was FITC-conjugated AffiniPure Goat Anti-Rabbit IgG (H+L).